XLON
STX
Market cap77mUSD
Oct 07, Last price
5.50GBP
1D
-1.79%
1Q
-13.39%
IPO
-96.59%
Name
Shield Therapeutics PLC
Chart & performance
P/E
—
P/S
1.16
EPS
—
Div yield, %
—
Shrs. gr., 5y
48.83%
Rev. gr., 5y
37.33%
Revenues
51m
+61.05%
Net income
-18m
L-32.27%
CFO
-9m
L+0.48%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Key people
Carl Andrew Sterritt
Chief Executive Officer, Director
Mark Sampson
Chief Medical Officer
Non-Executive Independent Director · since 2018
Non-Executive Independent Director · since 2018
Non-Executive Independent Director
IPO date
Feb 26, 2016
Employees
27
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
NORTHERN DESIGN CENTRE STUDIO 6, 3RD FLOOR
BALTIC BUSINESS QUARTER, GATESHEAD QUAYS
GATESHEAD, GAT NE8 3DF
GB
BALTIC BUSINESS QUARTER, GATESHEAD QUAYS
GATESHEAD, GAT NE8 3DF
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||